Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma

Background： Hepatocellular carcinoma （HCC） is one of the most prevalent fatal cancers in the world. Despite advances in early diagnosis and improvements in surgical techniques, the survival of patients with HCC even after resection is poor because of the high incidence of recurrences. Therefore, the identification of prognostic factors may be helpful in the development of new treatment protocols. Aims： To investigate HER-2/neu status in HCC by immunohistochemistry （IHC） and fluorescence in situ hybridisation （FISH）, and to explore the possibility of using trastuzumab in the treatment of HCC. Methods.. Eight hundred and sixty eight surgical samples from patients with primary HCC were examined for their HER-2/neu status. IHC for HER-2/neu was performed with the HercepTest kit; FISH analysis was performed with the PathVysion HER-2 DNA probe kit. The correlations between HER-2/neu overexpression and clinicopathological characteristics were analysed statistically. Results： HER-2/neu overexpression was detected in 21 （2.42%） of the 868 primary HCCs. Only one specimen showed HER-2/neu gene amplification by FISH. No significant associations were found between HER-2/neu overexpression and the clinicopathological parameters. Conclusions： There is a low frequency of HER-2/neu overexpression/amplification in HCC. There appears to be no role for HER-2/neu as a prognostic marker and no benefit of anti-HER-2/neu trastuzumab treatment in patients with HCC.     

Comparison of fluorescence <Emphasis Type="Italic">in situ</Emphasis> hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients

The accurate assessment ofa proto-oncogene, human epidermal growth factor receptor-2 gene （HER-2）, is extremely important for the therapy and prognosis of breast cancer. Currently, immunohistochemistry （IHC） is the method widely used for the detection of HER-2 protein. Fluorescence in situ hybridization （FISH） has been suggested to be a golden standard assay for HER-2 amplification. This study examined the expression and amplification of HER-2 in paraffin-embedded sections of breast cancer tissues, and compared the two methods on the measurement of HER-2 status. HER-2 gene and protein were determined in breast cancer samples from 52 Chinese women by FISH and IHC respectively. The findings indicated that the HER-2 gene amplification was found in 18 cases （34.6%） by FISH and the HER-2 protein over-expression （score 3＋） in 15 cases （28.8%） by IHC. hnmunohistochemically, 28.6% of the cases scored as 2＋ and 93.3% of the cases scored as 3＋ were HER-2-positive by FISH. There was a significant correlation between the HER-2 gene amplification and HER-2 protein over-expression in breast cancer （P〈0.005）. No correlation was noted between the HER-2 gene amplification and any of the clinicopathological parameters examined, including age, menopausal status, menarche age, tumor size, histological tumor type, histological grade, lymph node status, and the expression of ER and PR. It was concluded that the detection of HER-2 gene amplification in breast cancer by FISH is valuable and can compare with HER-2 protein detection by IHC.     

乳腺癌HER-2的表达与临床病理特征的关系

目的 探讨荧光原位杂交(FISH)和免疫组织化学(IHC)检测乳腺癌组织中人表皮生长因子受体2(HER-2)基因扩增及蛋白表达的一致性和相关性,及其与乳腺癌患者的临床病理特征的关系.方法 采用FISH法检测128例乳腺癌患者HER-2基因扩增状态,与IHC结果进行一致性及相关性分析,并比较其与乳腺癌患者的临床病理特征的相关性.结果 128例乳腺癌标本中,IHC与FISH结果符合率为90.6%,存在一致性(Kappa=0.405,P=0.000).两种检查结果呈正相关(r=0.655,P=0.000).ER表达与HER-2基因扩增及其蛋白表达状态呈负相关(r=-0.300,P=0.001;r=-0.223,P=0.011),而ER/PR状态与HER-2基因扩增状态呈负相关(r=-0.213,P=0.016).肿瘤分级与HER-2蛋白表达呈负相关(r=-0.293,P=0.008),而与HER-2基因扩增状态无关(P＞0.05).结论 IHC(+++)与基因扩增有较好的一致性,而IHC(+～++)者有必要进一步行FISH法检测基因状态.ER、ER/PR状态及肿瘤分级与HER-2基因扩增和(或)蛋白表达存在相关性.

Abstract：

Objective To investigate the concordance and correlation between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) assessment for HER-2 status in breast cancer patients and analyze their relationship to clinical characteristics. Methods A total of 128 samples of breast cancer tissue were analyzed retrospectively. FISH was employed to detect the HER-2 gene amplification. And the FISH findings were compared with IHC test results by analyzing the concordance and correlation between two results. And their relationships to the clinical characteristics were analyzed. Results The overall coincidence rate of IHC and FISH was 90. 6% ( kappa = 0.405, P = 0. 000 ). And the discordance was mainly found in the IHC ( + + ) group. A positive correlation was found between the two results ( r =0. 655, P=0. 000). The ER (estrogen receptor) expression was negatively correlated with HER-2 gene amplification and the expression of Her-2 protein ( r = - 0. 300, P = 0. 001;r = - 0. 223, P = 0.011 ).There was a negative correlation between ER/PR status and HER-2 gene amplification (r = -0.213, P=0.016). The similar results were found in subgroup analysis. Tumor grade was negatively correlated with the expression of Her-2 protein ( r = - 0. 293, P = 0. 008 ), but not with HER-2 gene amplification ( P ＞0. 05). Conclusion IHC is a preferred method to detect the Her-2 status in breast cancer. The strong positive expression ( + + + ) of HER-2 protein tested by IHC is strongly consistent with HER-2 gene amplification by FISH. But HER-2 gene amplification should be further detected by FISH in patients with HER-2 positive expression ( + - + + ) in order to guide the clinical diagnosis and treatment. ER, ER/PR (progesterone receptor)status and tumor grade are correlated with HER-2 gene amplification and/or the expression of Her-2 protein. This study helps improve the accuracy of judging HER-2 gene amplification according to the clinical and pathological features such as ER status and the results of IHC.     

Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3 149 Chinese patients

Background Accurate detection of human epidermal growth factor receptor 2 （HER2） expression and gene amplification is crucial for the application of HER2-specific therapy and for evaluating the response of patients with breast cancer.A uniform and standard procedure of immunohistochemistry （IHC） and fluorescence in situ hybridization （FISH） needs to be established for evaluating the HER2 status in breast cancer tissues for the treatment of patients with real HER2-positive tumors.The present multicenter study was aimed to examine the HER2 status in breast cancer specimens from Chinese patients using both IHC and FISH methods.Methods A multicenter study was performed on the HER2 status in 3 149 breast cancer specimens from different ethnic populations and areas in China by IHC and FISH assays.The potential association of HER2 status with demographic and clinical characteristics was analyzed.Results The positive rates for HER2 over-expression and HER2 amplification were 23.3％ and 27.5％ in this study,respectively.The concordance between IHC and FISH was 71.2％ （K=0.494,P ＜0.001）.Furthermore,72.9％ of specimens with IHC 2＋ were negative to FISH.The discordance rates among laboratories were from 5％ to 28％ for IHC and 1％ to 16％ for FISH.HER2 amplification was associated significantly with advanced tumor stage （Ⅲ or Ⅳ,P=0.002）,large tumor size （＞5 cm,P=0.002）,moderate and poor histological grades （P ＜0.0001）,post-menopause （P ＜0.0001）,ER-PR-（P=0.002）,and having ＞4 lymph nodes affected （P ＜0.0001） in this population.The positive rates of HER2 amplification in specimens from Man and Hui Chinese were significantly higher than that in other Chinese populations.There are slightly higher positive rates of HER2 expression and amplification in Chinese patients with breast cancer.Conclusion These findings may provide new insights into understanding the epidemiological features of HER2 expression and amplification,and may be valuable for clinical practice.     

荧光原位杂交和免疫组织化学技术检测乳腺癌HER-2基因扩增和蛋白表达状态对照研究

目的 比较荧光原位杂交(FISH)与免疫组织化学技术(IHC)在检测乳腺癌患者HER-2基因扩增和表达状态方面的应用.方法 采用FISH技术对66例IHC检测结果为HER-2基因过度表达(3+/2+)和低表达或无表达(1+/-)的乳腺癌石蜡切片进行HER-2基因扩增状态检测.结果 用FISH技术检测42例IHC结果显示HER-2基因过度表达(3+/2+)的标本,31例显示HER-2基因扩增,11例无扩增.检测24例IHC检测显示HER-2基因低度表达或无表达(1+/-)的标本,均未显示HER-2基因扩增.两组之间比较,Kappa系数为0.672,P<0.001,显示两项检测技术具有良好的一致性.另外.用FISH技术检测到部分病例显示17号染色体多体性,并且该多体性在HER-2高表达(3+/2+)的病例发生率显著高于低表达或无表达(1+/-)的病例(x~2=4.688,P=0.03).结论 FISH和ICH两项技术具有良好的一致性.IHC可作为HER-2基因扩增和表达状态检测的筛查手段.FISH技术可以作为检测HER-2基因扩增和17号染色体多体性的确诊手段.

Abstract：

Objective To evaluate the application of the immunohistochemistry (IHC) and the fluorescence in situ hybridization (FISH) in detecting the amplification and the expression of HER-2 gene in the breast cancer patients. Methods Sixty-six cases of paraffin-embeded breast cancer samples with overexpression, low or no expression of HER-2 gene as detected by IHC were analyzed for HER-2 gene amplification using FISH. Results Among the 42 samples with HER-2 gene overexpression (3+/2+) detected by IHC, 31 showed positive HER-2 gene amplification and 11 showed negative HER-2 gene amplification in FISH. In the 24 samples with low or no HER-2 gene expression (1+/-) detected by IHC, no HER-2 gene amplification was detected by FISH. The results of the two testing methods showed a good consistency with the kappa coefficient of 0.672 (P<0.001). We also found that the 17 chromosome polysomy in 42% of the samples and the incidence of 17 polysomy was significantly higher in the HER-2 gene overexpression (3+/2+) group than in low or no HER-2 gene expression (1+/-) group (x~2=4.688, P=0.03). Conclusion IHC can be used as a screening method for detecting HER-2 gene amplification, and FISH should be performed in cases of HER-2 gene overexpression (3+/2+) as detected by IHC.     

人表皮生长因子受体2在卵巢上皮性癌组织中的过表达及其预后价值

目的 探讨卵巢上皮性癌组织中人表皮生长因子受体(HER)-2/neu(c-erbB-2)的过表达及其与卵巢上皮性癌患者预后的关系.方法 采用免疫组化染色法检测77例卵巢上皮性癌组织中HER-2/neu的过表达,分析其与卵巢上皮性癌临床病理因素和生存时间之间的相关性.结果 卵巢上皮性癌组织中HER-2/neu的过表达率为28.6%.单因素分析显示,HER-2/neu过表达阳性患者的中位生存时间(25.7个月)明显短于HER-2/neu过表达阴性者(>34.1个月,P＝0.001).多因素分析显示, HER-2/neu过表达是影响患者预后的独立因素(P＝0.032).结论 HER-2/neu过表达在卵巢上皮性癌的发生和进展中起重要作用,是影响患者预后的独立危险因素. Abstract： Objective To investigate the overexpression of HER-2/neu(c-erbB-2) in epithelial ovarian cancer and the relationship between HER-2/neu overexpression and its prognostic significance. Methods The overexpression of HER-2/neu was detected by immunohistochemistry in 77 ovarian carcionma. Correlations between HER-2/neu overexpression and clinicopathologic features and survival time of epithelial ovarian cancer were analyzed. Results The overexpression rate of HER-2/neu in epithelial ovarian carcionma was 28.6%. In univariate analysis, significant difference in median survival time was observed between HER-2/neu overexpression patients and HER-2/neu expression negative patients(P＝0.001). In multivariate analysis, HER-2/neu overexpression was an independent prognostic factor of epithelial ovarian cancer(P＝0.032).Conclusions HER-2/neu overexpression plays an important role in the genesis and progression of epithelial ovarian carcionma. It is an independent prognostic factor of ovarian carcinoma.     

Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma

We attempted to compare the pattern of HER-2/neu, ER and PCNA in premenopausal and postmenopausal patients with breast carcinoma to identify potential biological differences. Five hundred and forty-eight samples from 318 premenopausal and 230 postmenopausal women with invasive ductal carcinoma of the breast were evaluated for HER-2/neu, ER and PCNA expression by immunohistochemistry. HER-2/neu expression showed 27.4% positivity in premenopausal and 24. 8% in postmenopausal women; there was no significant difference between the two groups （P〉0.05）. In contrast, HER-2/neu expression was found to be significantly associated with ER negativity in the two groups （P〈0.05 in premenopausal, P〈0. 001 in postmenopausal patients）. However, it was significantly associated with PCNA expression only in the postmenopausal group （P〈0. 001）. 54.4% showed premenopausal tumor cell ER positivity, whereas 64.3% of the postmenopausal group showed positivity. ER expression showed a significant correlation with patient menopausal status （P〈0.05）. The prevalence of PCNA positivity in the tumor cell components is slightly higher in postmenopausal compared to premenopausal women （P〉0.20）. The current study is consistent with reports from other groups regarding the correlation of HER-2/neu with adverse pathologic features and with expression of other markers in carcinoma. We also observed there was no trend toward increased HER-2/neu expression in either premenopausal or postmenopausal patients, i.e. there was similar HER-2/neu expression in the two groups. This suggests that HER-2/neu status could be used to determine assignment to specific intensive adjuvant therapy and evaluation of biological behavior in both pre- and postmenopausal patients with breast carcinoma.     

Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.

C-erbB-2(HER-2 / neu) proto-oncogene is mainly expressed in epithelial tissue and activated due to its amplification. Amplification of the C-erbB-2 proto-oncogene has been associated with poor prognosis in human ovarian cancer. Our study was to examine whether amplification is more frequently observed in ovarian cancer, or it is associated with poor prognosis of human ovarian cancer in China. The DNA of ovarian cancers was extracted and consequently digested with restriction endonuclease EcoRI, electrophoresed in 0.8% agarose gels and blotted onto nitrocellulose filter with Southern transfering method. It was then hybridized with a 32P-labelled C-erbB-2 probe and subsequently underwent autoradiography. The result has shown that the C-erbB-2(HER-2 / neu) gene was amplified in 8 of 26 human ovarian cancers (30.8%). The clinical data showed that all of the 8 cases with the amplified C-erbB-2 were in their advanced stage (III-IV). Five of the patients died from 2 to 4 months after operation. These data sugge     

Clinical and pathological features and surgical treatment of Budd-Chiari syndrome-associated hepatocellular carcinoma

Background Budd-Chiari syndrome （BCS） is characterized by liver sinusoidal congestion,ischemic liver cell damage,and liver portal hypertension caused by hepatic venous outflow constriction.The aim of this research was to investigate the clinicopathological features of BCS-associated hepatocellular carcinoma （HCC） and explore its surgical treatment and prognosis.Methods Clinical data from 38 patients with BCS-associated HCC who were surgically treated in our hospital from July 1998 to August 2010 were retrospectively analyzed.The clinicopathological features and prognosis of patients with BCS-associated HCC and surgical treatment for BCS-associated HCC were investigated.Results Compared to the patients with hepatitis B virus （HBV）-associated HCC,the patients with BCS-associated HCC showed a female predominance,and had significantly higher cirrhosis rate,higher incidence of solitary tumors,lower incidence of infiltrative growth,higher proportion of marginal or exogenous growth,lower rate of portal vein invasion,and higher degree of differentiation.Median survival was longer in patients with BCS-associated HCC （76 months） than in those with HBV associated HCC （38 months）.Of 38 patients with BCS-associated HCC,22 patients who received combined surgery mainly by liver resection plus cavoatrial shunts exhibited hepatic venous outflow constriction relief,while the other 16 patients only underwent liver resection.The combined surgery group had significantly longer survival and lower incidences of post-operative lethal complications （P 〈0.05）.Multivariate analysis showed that relief of hepatic venous outflow obstruction was a protective factor for survival of patients with BCS-associated HCC,whereas portal vein invasion was a risk factor.Conclusions BCS-associated HCC has a more favorable biological behavior and prognosis than HBV-associated HCC.For patients with BCS-associated HCC,tumor resection accompanied with relief of hepatic venous outflow obstruction can reduce the incidence of complications and extend survival.     

A/California/7/2009与A/California/4/2009病毒感染力比较

目的甲型H1N1流感病毒A/California/7/2009与A/California/4/2009病毒序列比较同源性在99%以上,本实验旨在比较两株病毒感染BALB/c小鼠研究感染力强弱。方法分别将A/California/7/2009(CA7)与A/California/4/2009(CA4)两株病毒分别连续10倍稀释后,对4~6周龄雌性BALB/c小鼠经乙醚麻醉后进行滴鼻攻毒,每个稀释度接种10只实验小鼠,测定CA7 MLD50为101.24/0.05 mL,检测小鼠感染、致病的多项指标,观察期为14 d。结果相同TCID50的CA7和CA4病毒感染小鼠,CA4感染小鼠后14 d内死亡率为20%,而CA7感染小鼠后8 d内死亡率为100%。CA7 106TCID50感染的小鼠病理表现为重度弥漫性间质性肺炎,CA4 106TCID50感染的小鼠病理表现为中度-重度间质性肺炎。结论在相同条件下,CA7感染力明显强于CA4。     

红葱的化学成分研究

目的 研究红葱Eleutherine americana 的化学成分。方法 采用硅胶柱色谱、Sephadex LH-20柱色谱及重结晶等方法,分离纯化红葱的化学成分,通过MS、NMR等波谱技术确定化合物结构。结果 确定了7个化合物的结构,分别为9-hydroxy-8-methoxy-1-methyl-1, 3-dihydronaphtho [2, 3-c] furan-4-O-β-D-glucopyranoside（1）、eleutherinoside A（2）、豆甾醇- 3-O-β-D-葡萄糖苷（3）、kadsuric acid（4）、豆甾醇（5）、1, 2-二羟基-8-甲氧基-3-甲基蒽醌（6）、9-methoxy-1, 3-dimethyl-1H-naphtho [2, 3-c] pyran-5, 10-dione（7）。结论 化合物1为新化合物,命名为红葱新苷。化合物3～5为首次从该植物中分离得到,化合物6和7为首次获得的新天然产物。     

金锦香的化学成分研究

目的 研究金锦香 Osbeckia chinensis 的化学成分。方法 利用硅胶柱色谱与Sephadex LH-20凝胶柱色谱进行分离和纯化,根据化合物的理化数据和波谱数据鉴定其结构。结果 从金锦香全草乙醇提取物中分离鉴定了16个化合物：3-甲氧基-鞣花酸-4-O-β-D-吡喃葡萄糖苷（1）、3, 3′-二甲氧基-鞣花酸-4-O-β-D-吡喃葡萄糖苷（2）、3, 3′, 4′-三甲氧基-鞣花酸-4-O- β-D-吡喃葡萄糖苷（3）、山柰酚-3-O-β-L-吡喃鼠李糖苷（4）、槲皮素-3-O-β-D-吡喃半乳糖苷（5）、槲皮素-3-O-β-L-吡喃鼠李糖苷（6）、山柰酚-6-C-β-D-吡喃葡萄糖苷（7）、槲皮素-3-O-β-L-吡喃鼠李糖苷-2″-乙酸酯（8）、山柰酚-3-O-β-D-吡喃葡萄糖苷-3″, 6″-二-E-(4-羟基)-肉桂酸酯（9）、4′-hydroxyflavone-3-O-(6-O-trans-p-coumaroyl)-β-D-glucopyranoside（10）、山柰酚-3-O- β-D-吡喃葡萄糖苷-6″-E-（4-羟基）-肉桂酸酯（11）、3β-hydroxy-9(11)-fernen-23-oic acid（12）、1, 2-dihydroxy-9(11)-arborinen-3-one（13）、cholest-5-ene-2, 3, 21-triol（14）、β-谷甾醇（15）、胡萝卜苷（16）。结论 除化合物5和16外,其余化合物均为首次从该植物中分离得到。     

Leprdb/db小鼠肾损伤机制探讨

  目的  探讨瘦素受体完全缺陷的Leprdb/db小鼠肾损伤机制。  方法  选取28周龄瘦素受体杂合缺陷的Leprdb/+（作为对照）与Leprdb/db雄性小鼠各10只,禁食8 h后,分别测量两组小鼠体质量、空腹血糖（FBG）和糖化血红蛋白（HbA1c）水平。小鼠经股动脉采血后处死。采用试剂盒检测血清中肌酐（CRE）、尿素氮（BUN）、超氧化物歧化酶（SOD）、还原型谷胱甘肽（GSH） 、丙二醛（MDA）的水平。酶联免疫吸附法（ELISA）检测血清中炎性细胞因子白细胞介素-1β（IL-1β）、单核细胞趋化因子-1（MCP-1)、肿瘤坏死因子-α（TNF-α）的表达水平。取肾进行病理观察。Western blot检测肾组织中核因子E2相关因子2（Nrf2）及核因子-κB（NF-κB）蛋白表达。提取肾组织细胞线粒体,Western blot检测线粒体中硫辛酸合成酶(lipoic acid synthase, LIAS)蛋白的表达水平。  结果  与Leprdb/+小鼠相比,Leprdb/db小鼠体质量、FPG、HbA1c、CRE、BUN水平均升高,差异有统计学意义（P<0.05）。病理观察发现,Leprdb/+小鼠肾细胞结构完整,而Leprdb/db小鼠肾小球体积增大,基底膜及毛细血管壁增厚,系膜细胞和系膜基质增多。与Leprdb/+小鼠相比,Leprdb/db小鼠血清中GSH水平降低,MDA和炎性因子MCP-1、IL-1β、TNF-α水平均升高,差异均有统计学意义（P<0.05）;Leprdb/db组小鼠肾脏线粒体内LIAS和肾组织中Nrf2蛋白表达量均降低,而NF-κB蛋白水平升高,差异均有统计学意义（P<0.05）。  结论  28周龄Leprdb/db小鼠存在氧化应激和炎症反应,肾损伤机制可能与LIAS调控Nrf2和NF-κB有关。     

鹿藿的化学成分研究

目的 研究鹿藿Rhynchosia volubilis的化学成分。方法 采用硅胶柱色谱法分离纯化,薄层色谱及现代波谱技术进行结构鉴定。结果 从其乙醇提取物的氯仿、醋酸乙酯萃取部分分离得到12个化合物,结构分别鉴定为β-谷甾醇（1）、胡萝卜苷（2）、苜蓿素（3）、5, 7, 3′-三羟基-4′-甲氧基异黄酮（4）,表儿茶素（5）、豆甾-5-烯-3β, 7α-二醇（6）、槲皮素（7）、芹菜素-7-O-β-D-葡萄糖苷（8）、木犀草素-7-O-β-D-葡萄糖苷（9）、没食子酸（10）、大豆苷元（11）和大萼赝靛素（12）。结论 所有化合物均为首次从该植物中分离得到。     

毛酸浆浆果的化学成分研究

目的 研究毛酸浆Physalis pubescens浆果的化学成分。方法 利用反复硅胶柱色谱、Sephadex LH-20凝胶柱色谱、中压柱色谱及半制备高效液相色谱等方法分离纯化,根据核磁共振谱、质谱等谱学数据鉴定化合物结构。结果 从毛酸浆浆果中分离得到16个化合物,分别鉴定为3, 7, 3′-三甲基槲皮素（1）、山柰酚（2）、金圣草酚（3）、槲皮素-3-O-β-D-吡喃葡萄糖苷（4）、2α, 3β, 23-三羟基-12-烯-28-齐墩果酸（5）、白头翁皂苷A（6）、白头翁皂苷D（7）、咖啡酸（8）、1-O-咖啡酰基-β-D-吡喃葡萄糖（9）、N-反式-阿魏酰酪胺（10）、新橄榄脂素（11）、梣皮树脂醇（12）、松脂醇（13）、蔗糖（14）、尿苷（15）、β-谷甾醇（16）。结论 化合物5～7、9～15为首次从酸浆属植物中分离得到,化合物3、8为首次从该植物中分离得到。     

乌拉尔甘草化学成分研究

目的 研究乌拉尔甘草Glycyrrhiza uralensis根的化学成分。方法 利用硅胶、聚酰胺、MCI、ODS、Sephadex LH-20柱色谱，RP-HPLC等技术对乌拉尔甘草70%乙醇提取物的醋酸乙酯萃取部位进行分离纯化，根据化合物的理化性质和波谱数据进行结构鉴定。结果 分离得到14个化合物，分别鉴定为3, 7-二甲基甘草黄酮醇（1）、甘草宁I（2）、甘草香豆酮（3）、8-甲雷杜辛（4）、2′-hydroxyisolupalbigenin（5）、异驴食草酚（6）、去氢粗毛甘草素D（7）、glycyrin（8）、甘草酚（9）、刺甘草查耳酮（10）、甘草查耳酮B（11）、isoangustone A（12）、甘草宁G（13）、5, 7, 4′-三羟基-6, 8-二异戊烯基异黄酮（14）。结论 化合物1为新化合物，化合物2～7首次从该植物中分离得到。     

藏药樱草杜鹃的黄酮类成分研究

目的 研究藏药樱草杜鹃Rhododendron primulaeflorum的叶和嫩枝的黄酮类成分。方法 利用色谱方法分离和纯化化合物,并通过光谱方法及理化性质鉴定其结构。结果 从樱草杜鹃中分离得到10个黄酮类化合物,分别鉴定为槲皮素-3- O-β-D-刺槐双糖-7-O-β-D-葡萄糖苷（1）、反-花旗松素-3-O-α-吡喃阿拉伯糖苷（2）、杨梅素-3′-O-β-D-吡喃木糖苷（3）、棉花皮素-3-O-β-D-吡喃半乳糖苷（4）、金丝桃苷（5）、槲皮素（6）、花旗松素（双氢槲皮素,7）、(?)-表儿茶素（8）、杨梅素（9）、双氢杨梅素（10）。结论 除化合物2、6外,其他化合物均首次从该植物中分离得到。     

冬青叶兔唇花化学成分研究

目的 对唇形科兔唇花属植物冬青叶兔唇花Lagochilus ilicifolius全草的化学成分进行研究。方法 运用多种色谱手段进行分离纯化,通过波谱解析进行结构鉴定。结果 从冬青叶兔唇花全草95%乙醇提取物中分离鉴定了10个化合物,分别为丁香脂素（1）、东莨菪素（2）、槲皮素（3）、杨梅素（4）、芦丁（5）、异槲皮苷（6）、山柰酚-3-O-芸香糖苷（7）、山柰酚-3-O-β-D-(6″-O-p-香豆素)葡萄糖苷（8）、8-O-乙酰基哈帕苷（9）、哈帕苷（10）。结论 首次从冬青叶兔唇花全草中分离鉴定了10个化合物,其中化合物1、7、8为首次从兔唇花属植物中分得。